Regarding Alzheimer-disease: the new antibody Lecanemab is NOT a game-changer. It only slows down the disease in a modest way, it is extremely expensive, is has major side-effects, like brain
bleeding and brain oedema and requires a whole infrastructure for infusion treatment which does not make it available to the wider public. Being a homozygote ApoE4-gene carrier (15% of all
Alzheimer patients) is even a contraindication for Lecanemab. Far more effect in treatment and prevention of this terrible disease is a healthy lifestyle: Non-smoking, very minor alcohol
consumption, mediterranean diet, weight control and aerobe exercising and exercising the brain. Early diagnostics is already available: Amyloid PET-scan and lumbar puncture for phosphorilated
tau/amyloid beta 42 ratio in cerebrospinal fluid. Soon available as a blood serum marker and a game-changer in diagnosing early Alzheimers might be pTau217 which might give us the option
not to prevent the disease but to slow it down significantly by then reducing our risk factors.
Risk factors for developing Alzheimer disease - aside of a genetic predisposition:Medical risk factors:
Depression, Diabetes mellitus, Dyslipidaemia, Hearing and visual loss, Hypertension, Obstructive sleep apnoea, Smoking.
Environmental risk factors:
Diet, Loneliness, Physical inactivity, Pollution, Poor education, Sedentarism, Stress.
Korczyn, A.D., Grinberg, L.T. Is Alzheimer disease a disease?. Nat Rev Neurol 20, 245–251 (2024). https://doi.org/10.1038/s41582-024-00940-4